November 2014

New Product - Sovaldi

Sovaldi (sofosbuvir) is a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sovaldi is indicated for the treatment of adults with chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. When Sovaldi is used in combination with peginterferon alfa/ ribavirin or ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Sovaldi is available as 400 mg tablets in packs of 28’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629